CellMax Life Inc (合度精密生物科技) yesterday launched a blood-testing service in Taiwan that focuses on screening for early-stage cancer.
The company’s flagship product, CellMax CRC-Protect, is a multi-biomarker blood test aimed at the early detection of colorectal cancer.
The product has been used by more than 500 patients at a number of local hospitals, including Linkou Chang Gung Memorial Hospital (林口長庚紀念醫院).
“We aim to transform cancer care away from expensive, intractable late stages to early, more treatable stages,” CellMax Life co-founder and chief operating officer Atul Sharan told a news conference in Taipei yesterday.
Much of the biotechnology sector focuses on expensive late-stage drugs that might not be accessible in developing countries, while survival rates for patients with late-stage cancer diminish rapidly, Sharan added.
The company’s proprietary CMx technology platform screens for cancer by detecting traces of circulating early-stage tumor cells that are shed from the primary tumor site into the bloodstream, CellMax science team chief Shao Hung-jen (邵宏仁) said.
Abnormal cells should be detected by the screening product before they turn into precancerous cells and metastasize, Shao said.
The platform uses a biomimetic, lipid-bilayer coated microfluidic chip to identify circulating tumor cells cells in patients’ blood samples, Shao said.
As the test requires a blood sample, it is an attractive option for patients who are averse to fecal occult blood tests, stool samples or colonoscopies, Shao said.
However, the test is not intended to replace existing examinations, but is designed to be used as an additional diagnostic tool by physicians, Shao said.
A woman said in a testimonial video that after using a CellMax screening product and consulting her physician, she agreed to have intestinal surgery that removed eight polyps and minimized her chances of contracting colon cancer.
Chao recommended that people who are at high risk of developing colon cancer undergo annual screening, adding that each of the firm’s tests costs about NT$15,000.
CellMax’s other products include testing of genetic risk, liquid biopsies and recurrence monitoring.
The company also announced US$9 million in series A-1 venture funding to scale commercial operations of its blood test product portfolio.
The funding was led by Silicon Valley-based Artiman Ventures and several Taiwanese venture investors, including Acer founder and former chairman Stan Shih (施振榮).
The company has so far accumulated US$14 million in venture capital.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
MAJOR BENEFICIARY: The company benefits from TSMC’s advanced packaging scarcity, given robust demand for Nvidia AI chips, analysts said ASE Technology Holding Co (ASE, 日月光投控), the world’s biggest chip packaging and testing service provider, yesterday said it is raising its equipment capital expenditure budget by 10 percent this year to expand leading-edge and advanced packing and testing capacity amid strong artificial intelligence (AI) and high-performance computing chip demand. This is on top of the 40 to 50 percent annual increase in its capital spending budget to more than the US$1.7 billion to announced in February. About half of the equipment capital expenditure would be spent on leading-edge and advanced packaging and testing technology, the company said. ASE is considered by analysts